R&D Center
HLB PHARMA
R&D pipeline
R&D center of HLB PHARMA Co., Ltd. is
Leading the development of patient-centric drug , based on advanced Drug Delivery
System for the degenerative diseases and chronic diseases
| Category | Projects | Indications | Formulation | Pre-clinical | Clinical Phase 1 | Clinical Phase 2 | Clinical Phase 3 | Patent Information |
|---|---|---|---|---|---|---|---|---|
| Long-acting injections | MFP-008 | Cancer |
|
KR 10-1936040 PCT/KR2019/004800 |
||||
| MFP-037 | Dementia |
|
KR application (2020.2Q) |
|||||
| MFP-013 | Parkinson’s disease |
|
KR 10-2018-0144994 PCT/KR2019/014361 KR application (2020.2Q) |
|||||
| MFP-024 | Anticoagulants |
|
KR 10-2044676 KR 10-2045721 PCT application (2020.1Q) |
|||||
TOP
- HLB PHARMA Co., Ltd.
- 778-1 Ilpaedong, Gyeonggangro, Namyangju-si, Gyeonggi-do, Korea
- CEO : Jae Hyung Park
- Headquater(Namyangju Plant) : 27, Gyeonggang-ro, Namyangju-si, Gyeonggi-do, Republic of Korea | TEL: +82-31-557-0001
- Seoul Office : 9F MK Tower, 67, Jeongui-ro, Songpa-gu, Seoul, Republic of Korea | TEL: +82-2-411-1500
- Hyangnam Plant : 35, Jeyakgongdan 2-gil, Hyangnam-eup, Hwaseong-si, Gyeonggi-do, Republic of Korea | TEL: +82-31-630-4001
- COPYRIGHT(C) HLB PHARMA. ALL RIGHTS RESERVED.
